Coherus BioSciences (FRA:8C5) Debt-to-Equity : -5.88 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Debt-to-Equity?

Coherus BioSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €162.7 Mil. Coherus BioSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €280.0 Mil. Coherus BioSciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €-75.3 Mil. Coherus BioSciences's debt to equity for the quarter that ended in Mar. 2024 was -5.88.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Coherus BioSciences's Debt-to-Equity or its related term are showing as below:

FRA:8C5' s Debt-to-Equity Range Over the Past 10 Years
Min: -56.84 Med: 1.48 Max: 34.26
Current: -5.88

During the past 12 years, the highest Debt-to-Equity Ratio of Coherus BioSciences was 34.26. The lowest was -56.84. And the median was 1.48.

FRA:8C5's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs FRA:8C5: -5.88

Coherus BioSciences Debt-to-Equity Historical Data

The historical data trend for Coherus BioSciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Debt-to-Equity Chart

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.79

1.48

4.29

-3.50

-2.49

Coherus BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-2.44	-2.74	-3.58	-2.49	-5.88

Competitive Comparison of Coherus BioSciences's Debt-to-Equity

For the Biotechnology subindustry, Coherus BioSciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Debt-to-Equity falls into.

Coherus BioSciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Coherus BioSciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.967	+	438.965)	/	-177.371
	=	-2.49

Coherus BioSciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(162.666	+	280.004)	/	-75.296
	=	-5.88

Coherus BioSciences (FRA:8C5) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Coherus BioSciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (FRA:8C5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines